ACM
MNPR icon

ADAR1 Capital Management’s Monopar Therapeutics MNPR Stock Holding History

ADAR1 Capital Management’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.1M Sell
217,595
-46,683
-18% -$2.89M 0.92% 22
2026
Q1 		$14.5M Buy
264,278
+30,370
+13% +$1.83M 0.85% 25
2025
Q4 		$15.3M Buy
233,908
+103,909
+80% +$8.49M 1.12% 18
2025
Q3 		$10.6M Buy
129,999
+29,025
+29% +$1.3M 1% 22
2025
Q2 		$3.61M Buy
100,974
+200
+0.2% +$7.26K 0.55% 41
2025
Q1 		$3.67M Sell
100,774
-29,263
-23% -$1.05M 0.68% 41
2024
Q4 		$2.86M Buy
+130,037
New +$2.18M 0.57% 39

Other funds holding MNPR

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

ADAR1 Capital Management's MNPR Position: Q2 2026 in Review

ADAR1 Capital Management reduced its Monopar Therapeutics (MNPR) stake by 18% in Q2 2026, selling an estimated $2.89M and leaving 217,595 shares worth $20.1M. The position accounts for 0.92% of the portfolio, ranked #22.

ADAR1 Capital Management first reported a position in MNPR in Q4 2024 and has held it in 7 quarters since. 96 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • ADAR1 Capital Management held 217,595 shares of Monopar Therapeutics worth $20.1M as of Q2 2026.
  • ADAR1 Capital Management sold 46,683 Monopar Therapeutics shares in Q2 2026, an estimated $2.89M.
  • Monopar Therapeutics made up 0.92% of ADAR1 Capital Management's portfolio in Q2 2026, its #22 holding.
  • ADAR1 Capital Management first reported a position in Monopar Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 96 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.